Compare ABRDN Physical Gold Shares ETF (SGOL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ABRDN Physical Gold Shares ETF vs BIO-TECHNE Corp — how do they compare? ABRDN Physical Gold Shares ETF trades at $41.69, while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp pays a 0.44% dividend while ABRDN Physical Gold Shares ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| SGOL | TECH | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $51.41 | $72.29 |
52-Week Low | $31.61 | $43.31 |
Market Cap | — | $11.24B |
Enterprise Value | — | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOL, a US-listed gold ETF, trades at $41.35, up 2.22% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights gold's rebound potential, driven by central bank buying and dovish Fed expectations. The stock shows strong support at $41 and resistance at $42, with institutional sentiment leaning positive amid macroeconomic support for precious metals.
Outlook remains cautiously optimistic as gold benefits from lower real yields and geopolitical factors, though overbought conditions near-term pose a risk. Investment appeal hinges on sustained macroeconomic trends, while volatility from dollar movements and profit-taking presents challenges for short-term holders.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
